-
Na June 11, Kelun-Biotech kwupụtara na ha emepụtala ọgwụ TROP2 ADC sac-TMT (佳泰莱) nke aka ha mepụtara n'onwe ha, yana ọgwụ mgbochi monoclonal PD-L1 tagitanlimab (科泰莱"), enyerela aha Breakthrough Therapy (BTD) site na Center for Drug Evaluation (CDE) nke National Med...GỤKWUO»
-
Na Mee 29, National Medical Products Administration (NMPA) kwadoro ahịa Zanidatamab, nke BeiGene nyere, maka ọgwụgwọ nke ndị ọrịa nwere ọrịa kansa biliary tract nke a na-apụghị ịgbanahụ n'ógbè ma ọ bụ nke metastatic metastatic (BTC) bụ ndị natara ọgwụgwọ sistemu na mbụ ma gosipụta HER2 dị elu...GỤKWUO»
-
Na Juun 04, 2025, Akeso kwupụtara na National Medical Products Administration (NMPA) akwadola ọgwụ mgbochi PD-1/CTLA-4 nke ụlọ ọrụ ahụ, cadonilimab, maka ọgwụgwọ mbụ nke kansa cervical na-adịgide adịgide, na-emegharị ugboro ugboro, ma ọ bụ metastatic, yana platinu...GỤKWUO»
-
Na Mee 29, National Medical Products Administration (NMPA) kwadoro ọgwụ HER2-targeted antibody-drug conjugate (ADC) trastuzumab rezetecan (SHR-A1811) maka ahịa. A na-egosi ya dị ka ọgwụgwọ otu maka ọgwụgwọ ndị toro eto nwere ndị agadi nwere ndị agadi nwere ọrịa na-adịghị ahụkebe na mpaghara ma ọ bụ ndị na-abụghị obere ...GỤKWUO»
-
Na Mee 21, 2025, InnoCare Pharma kwupụtara na China National Medical Products Administration (NMPA) enyela ikike maka Minjuvi® (tafasitamab), ọgwụ CD19 nke Fc gbanwere nke na-elekwasị anya na monoclonal antibody, yana lenalidomide, yana Minjuvi monotherapy, maka ọgwụ mgbochi ọrịa...GỤKWUO»
-
Na Mee 22, 2025, Allist Pharmaceuticals kwupụtara na ọgwụ ọhụrụ ya bụ Airuikai (Glecirasib Citrate Tablets), nke bụ ọgwụ mgbochi KRAS-G12C, enwetala ikike maka mmalite ahịa site n'aka National Medical Products Administration (NMPA). Nkwenye a na-enye ohere ka ejiri Airuikai mee ọgwụgwọ ahụ...GỤKWUO»
-
Na Mee 22, 2025, Kelun Bio kwupụtara na ngwa maka ihe ngosi ọhụrụ nke antigen 2 (TROP2) nke na-eduzi antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, nke a makwaara dị ka SKB264/MK – 2870) (®) anabatala site na Center for Drug Evaluation (...GỤKWUO»
-
N'ọgụ dị ogologo megide ọrịa kansa, ngwa agha ọhụrụ na-alụso ọrịa kansa na-apụta mgbe niile, na-eweta olileanya ọhụrụ nye ndị ọrịa N'agha dị ogologo n'etiti ụmụ mmadụ na ọrịa kansa, ngwa agha ọhụrụ na-alụso ọrịa kansa na-apụta otu otu, na-eweta olileanya ọhụrụ nye ndị ọrịa. Dịka ihe ọhụrụ na-egbuke egbuke...GỤKWUO»
-
N'afọ 2021, otu onye ọrịa kansa pancreas dị afọ 67 mepụtara ọrụ ebube ahụike. Mgbe ọ nwesịrị ịwa ahụ, ọtụtụ ugboro nke chemotherapy, na ọdịda nke ọgwụgwọ TIL, nnwale ahụike nke ọgwụgwọ mkpụrụ ndụ TCR-T o sonyere na ya mere ka metastases akpa ume belata site na 72% n'ime ọnwa isii...GỤKWUO»
-
Na Mee 12, 2025, CARsgen kwupụtara data ahụike mbụ maka CT0596, CAR-T nke BCMA lekwasịrị anya na allogeneic mepụtara site na iji ikpo okwu THANK-u Plus™. A na-enyocha CT0596 ugbu a na ọmụmụ nyocha mbụ maka ọrịa myeloma multiple relaxative/refractory (R/R MM) ma ọ bụ relaxative/refractor...GỤKWUO»
-
Na Mee 9, 2025, Hansoh Pharmaceutical kwupụtara na a kwadoro ihe ngosi ọhụrụ maka Ameile (mkpụrụ ọgwụ almonertinib mesylate) maka ire ahịa. Ihe ngosi ọhụrụ a bụ maka ọgwụgwọ ndị okenye nwere ọrịa kansa akpa ume na-abụghị obere sel (NSCLC) nke etuto ahụ nwere ihe na-eme ka epidermal growth factor...GỤKWUO»
-
Na Mee 1, 2025, Hansoh Pharmaceutical kwupụtara na ọgwụ B7-H4 nke otu ahụ mepụtara n'onwe ya maka ọgwụ mgbochi-ọgwụ (ADC) HS-20089 maka ịgba ọgwụ enwetala ikike itinye ya dị ka ọgwụ Breakthrough-Therapy-Designed site na National Medical Products Administration (NMPA) nke China, nke a na-akpọ "Breakthrough-Therapy-Designed Drug Conjugate",...GỤKWUO»
Ụlọ ọrụ ahụike jikọrọ aka nke Ụlọ Ọgwụ Ọrịa Kansa nke Beijing